RESUMO
Low-volume sampling devices offer the promise of lower discomfort and greater convenience for patients, potentially reducing patient burden and enabling decentralized clinical trials. In this study, we determined whether low-volume sampling devices produce pharmacokinetic (PK) data comparable to conventional venipuncture for a diverse set of monoclonal antibodies (mAbs) and small molecules. We adopted an open-label, non-randomized, parallel-group, single-site study design, with four cohorts of 10 healthy subjects per arm. The study drugs, doses, and routes of administration included: crenezumab (15 mg/kg, intravenous infusion), etrolizumab (210 mg, subcutaneous), GDC-X (oral), and hydroxychloroquine (HCQ, 200 mg, oral). Samples were collected after administration of a single dose of each drug using conventional venipuncture and three low-volume capillary devices: TassoOne Plus for liquid blood, Tasso-M20 for dry blood, both applied to the arm, and Neoteryx Mitra® for dry blood obtained from fingertips. Serum/plasma concentrations from venipuncture and TassoOne Plus samples overlapped and PK parameters were comparable for all drugs, except HCQ. After applying a baseline hematocrit value, the dry blood concentrations and PK parameters for the two monoclonal antibodies were comparable to those obtained from venipuncture. For the two small molecules, two bridging strategies were evaluated for converting dry blood concentrations to equivalent plasma concentrations. A baseline hematocrit correction and/or linear regression-based correction was effective for GDC-X, but not for HCQ. Additionally, the study evaluated the bioanalytical data quality and comparability from the various collection methods, as well as patient preference for the devices.
Assuntos
Coleta de Amostras Sanguíneas , Humanos , Masculino , Feminino , Adulto , Coleta de Amostras Sanguíneas/métodos , Flebotomia/métodos , Anticorpos Monoclonais/farmacocinética , Anticorpos Monoclonais/administração & dosagem , Hidroxicloroquina/farmacocinética , Hidroxicloroquina/sangue , Hidroxicloroquina/administração & dosagem , Adulto Jovem , Pessoa de Meia-Idade , Voluntários Saudáveis , Administração Oral , Teste em Amostras de Sangue Seco/métodosRESUMO
While low-volume sampling technologies offer numerous advantages over venipuncture, implementation in clinical trials poses technical and logistical challenges. Bioanalytical methods were validated for measuring the concentration of crenezumab and etrolizumab in dried blood samples collected using Mitra and Tasso-M20. The data generated demonstrate that the concentrations of crenezumab and etrolizumab in dried blood collected by either device could be determined using calibrators prepared in serum. Drug concentrations from dried blood were converted to serum concentrations using patient hematocrit levels. Contract Research Organization experience in sample handling and analysis allowed us to compare differences between various low-volume sampling technologies. This study evaluated challenges and presented potential solutions for use of different low-volume sampling technologies for pharmacokinetic analysis.
Assuntos
Teste em Amostras de Sangue Seco , Manejo de Espécimes , Humanos , Teste em Amostras de Sangue Seco/métodos , Manejo de Espécimes/métodos , Flebotomia , Tecnologia , Espectrometria de Massas em Tandem/métodos , Coleta de Amostras Sanguíneas/métodosRESUMO
Aim: Development of recombinant fusion proteins as drugs poses unique challenges for bioanalysis. This paper describes a case study of a glycosylated fusion protein, where variable glycosylation, matrix interference and high sensitivity needs posed unique challenges. Results: Six different assay configurations, across four different platforms were evaluated for measurement of drug concentrations. Two platforms that achieved the assay requirements were Simoa HD-1 and immune-capture LC-MS/MS-based assay. Conclusion: Both, Simoa HD-1 and the mass spectrometry-based methods were able to detect total drug by providing the adequate matrix tolerance, required sensitivity and detection of all the various glycosylated fusion proteins to support clinical sample analysis. The mass spectrometry-based method was selected due to robustness and ease of method transfer.
Assuntos
Ensaio de Imunoadsorção Enzimática/métodos , Ácido N-Acetilneuramínico/farmacocinética , Glicosilação , HumanosRESUMO
Background: Low volume sampling technologies have come a long way; however, their uptake has been slow due to logistical and perceived implementation challenges. Additional studies are needed to overcome these barriers. Materials & methods/results: Here we present two studies where different sampling technologies were evaluated to determine the feasibility of their implementation. First, we evaluated pharmacokinetic profiles for anti-gD in rats using three tail bleed sampling methods, glass capillary tubes, Shimadzu MSW2® and the Neoteryx Mitra® microsampler. Second, we evaluated two low volume-sampling methods to measure drug levels from patients treated with anti-A therapeutic. This evaluation used whole blood finger pricks for Neoteryx Mitra and plasma from capillary blood using TASSO OnDemand technology to compare results to established venipuncture collection method. Conclusion: These studies evaluate the feasibility and considerations for implementation of different low volume sampling technologies.
Assuntos
Anticorpos Monoclonais/sangue , Coleta de Amostras Sanguíneas , Animais , Ensaio de Imunoadsorção Enzimática , Humanos , Flebotomia , RatosRESUMO
Aim: Current blood monitoring methods require sample collection and testing at a central lab, which can take days. Point of care (POC) devices with quick turnaround time can provide an alternative with faster results, allowing for real-time data leading to better treatment decisions for patients. Results/Methodology: An assay to measure monoclonal antibody therapeutic-A was developed on two POC devices. Data generated using 75 serum samples (65 clinical & ten spiked samples) show correlative results to the data generated using Gyrolab technology. Conclusion: This case study uses a monoclonal antibody therapeutic-A concentration assay as an example to demonstrate the potential of POC technologies as a viable alternative to central lab testing with quick results allowing for real-time decision-making.
Assuntos
Anticorpos Monoclonais/imunologia , Sistemas Automatizados de Assistência Junto ao Leito/normas , HumanosRESUMO
Aim: Bedside or point-of-care testing (POCT) provides immediate results, allowing for rapid clinical decision making and management of critically ill patients. IL-6 is a central mediator in cytokine release syndrome and sepsis, two potentially life-threatening events. A real-time point-of-care measurement of IL-6 readily available in hospitals and/or to clinicians could provide a valuable tool for decision making. Materials & methods: An IL-6 assay is developed on a POCT device (Proxim, CA, USA), with comparison data measured by ELISA, Ella, and the Roche Cobas. Results: Samples evaluated on a Proxim POCT device showed good correlation with data from multiple platforms. Conclusions: An IL-6 point-of-care assay was developed as potential tool for rapid clinical decision making and management of patients with sepsis and/or cytokine release syndrome.
Assuntos
Síndrome da Liberação de Citocina/sangue , Interleucina-6/sangue , Testes Imediatos , Sepse/sangue , Síndrome da Liberação de Citocina/diagnóstico , Desenho de Equipamento , Humanos , Limite de Detecção , Sepse/diagnósticoRESUMO
A cell-based assay employing Madin-Darby canine kidney cells stably expressing human neonatal Fc receptor (FcRn) heavy chain and ß2-microglobulin genes was developed to measure transcytosis of monoclonal antibodies (mAbs) under conditions relevant to the FcRn-mediated immunoglobulin G (IgG) salvage pathway. The FcRn-dependent transcytosis assay is modeled to reflect combined effects of nonspecific interactions between mAbs and cells, cellular uptake via pinocytosis, pH-dependent interactions with FcRn, and dynamics of intracellular trafficking and sorting mechanisms. Evaluation of 53 mAbs, including 30 marketed mAb drugs, revealed a notable correlation between the transcytosis readouts and clearance in humans. FcRn was required to promote efficient transcytosis of mAbs and contributed directly to the observed correlation. Furthermore, the transcytosis assay correctly predicted rank order of clearance of glycosylation and Fv charge variants of Fc-containing proteins. These results strongly support the utility of this assay as a cost-effective and animal-sparing screening tool for evaluation of mAb-based drug candidates during lead selection, optimization, and process development for desired pharmacokinetic properties.
Assuntos
Anticorpos Monoclonais Humanizados/farmacocinética , Antígenos de Histocompatibilidade Classe I/imunologia , Receptores Fc/imunologia , Transcitose/imunologia , Animais , Anticorpos Monoclonais Humanizados/imunologia , Anticorpos Monoclonais Humanizados/metabolismo , Bioensaio/métodos , Cães , Glicosilação , Humanos , Imunoglobulina G/metabolismo , Células Madin Darby de Rim Canino , CamundongosRESUMO
AIM: Etrolizumab, a humanized monoclonal antibody, has demonstrated clinical remission in a Phase II study of ulcerative colitis patients. In the Phase III program, a second indication, Crohn's disease was added. The pharmacokinetic ELISA used in the Phase I/II studies in normal human and ulcerative colitis sera exhibited matrix interference in the Crohn's disease population, necessitating implementation of a new technology. Methodology & results: Optimization of the original ELISA and assay redevelopment using different antibody pairs did not result in substantive improvements, necessitating implementation of an alternative technology for assay development. CONCLUSION: We highlight the challenges encountered with optimization/redevelopment of the original ELISA and discuss results of the new assay on the Gyros platform.
Assuntos
Doença de Crohn/metabolismo , Ensaio de Imunoadsorção Enzimática/instrumentação , Imunoensaio/instrumentação , Dispositivos Lab-On-A-Chip , Animais , Artefatos , Doença de Crohn/sangue , Humanos , Distribuição TecidualRESUMO
BACKGROUND: In the bioanalytical laboratory, challenges associated with manual, repetitive, labor-intensive processes can be addressed by powerful automated liquid handlers; however, their implementation has been difficult due to lack of efficient integration into laboratory workflows. Faster throughput is afforded to ligand binding assay (LBA) technologies via enhanced automation, but the upstream sample processing still remains a bottleneck. To be truly efficient, these technologies must be incorporated into a laboratory information management system (LIMS) to streamline data analysis and reporting. RESULTS: Three off-the-shelf technologies that aid in improving bioanalytical laboratory efficiencies were utilized with minimal customization to streamline the sample analysis process. Information extracted via a sequence file from the LIMS run was utilized to perform the sample processing on the automated liquid handler. A file conversion tool converted the sequence files that allowed for sample processing and preparing the assay ready plate. The plate was then transferred to the LBA microfluidics platform to run the experiments. The integration was tested using a LBA PK assay that demonstrated good sample dilution and assay performance. CONCLUSION: We successfully integrated LIMS with an automated liquid handler and a microfluidics platform to automate the sample analysis process in the bioanalytical laboratory. The utilization of off-the-shelf technologies with minimal customization requires minimal resources from laboratory scientists. It may be possible to implement this approach for other analytical platforms.
Assuntos
Técnicas de Química Analítica/métodos , Informática/métodos , Técnicas de Química Analítica/normas , Laboratórios , Controle de Qualidade , Reprodutibilidade dos TestesRESUMO
We have developed a LabChip-based plasmid assay that runs on the Agilent 2100 Bioanalyzer. The assay determines the sizes and relative concentrations of the multiple forms of plasmid samples. Twelve samples can be analyzed on each chip in an automated run lasting approximately 30min. By using a supercoiled DNA sizing standard of 2-16kb, the size of the analyzed plasmid can be determined. The resulting MW has a relative standard deviation (CV) <5% and error <5%. Plasmids from 2-8kb can be separated with resolution better than 1kb. Topological isoforms in a plasmid sample can also be separated. However, due to differential staining, the heterogeneity of plasmid samples can only be measured if the signal of each isomer peak can be calibrated with pure standards for every isomer form. For a typical plasmid preparation which predominately is in the supercoiled form, the normalized corrected peak area for the supercoiled form correlates with the plasmid concentration in a broad range of 1-100ng/microl. The measurement is semiquantitative with a CV lower than 20%. A number of applications of this assay on a Labchip will be shown.